|
Coronary heart disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plasminogen activator inhibitor type-1 (PAI-1) is a <u>ser</u>ine <u>p</u>rotease <u>in</u>hibitor (serpin) implicated in numerous pathological processes, including coronary heart disease, arterial and venous thrombosis, and chronic fibrotic diseases.
|
30510136 |
2019 |
|
Coronary heart disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings provide a novel regulatory mechanism of miR-30c in regulating PAI-1/VN interactions and that may serve as a diagnostic biomarker of DM2 that is complicated with CHD.
|
31760103 |
2019 |
|
Coronary heart disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Elevated PAI-1 antigen levels have been identified as a potential biomarker for coronary artery disease and metabolic syndrome while being modulated by a number of atherosclerotic risk factors.
|
29494856 |
2018 |
|
Coronary heart disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the systematic meta-analysis, the highest quantile of blood PAI-1 level was associated with higher CHD risk comparing with the lowest quantile (odds ratio=2.17; 95% CI: 1.53, 3.07) in an age- and sex-adjusted model.
|
28550093 |
2017 |
|
Coronary heart disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Polymorphism and synergism of angiotensin-converting enzyme (ACE) and plasminogen activator inhibitor-1 (PAI-1) genes in coronary artery disease.
|
25501306 |
2015 |
|
Coronary heart disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, HDL from CHD and ACS patients loses the ability of healthy HDL to suppress TF and to increase TFPI and t-PA and instead enhances PAI-1 and arterial thrombus formation.
|
25056722 |
2014 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Plasminogen activator inhibitor-1 4G/5G gene polymorphism and coronary artery disease in the Chinese Han population: a meta-analysis.
|
22496752 |
2012 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Using our method, we are able to detect GE interaction of SERPINE1 and body mass index (BMI) on CHD, which has not been reported.
|
21241273 |
2011 |
|
Coronary heart disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Accordingly, beneficial pleiotropic effects of statins on coronary artery disease may be attributable, in part, to attenuation of overexpression of PAI-1 mediated by the 3'-UTR in syndromes of insulin resistance (such as the metabolic syndrome) and type 2 diabetes.
|
20299979 |
2010 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Evidence suggested that the plasma levels of SERPINE1 modulate the risk of coronary artery disease; furthermore, that the 4G5G polymorphism affects the expression of the SERPINE1 gene.
|
20017074 |
2009 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Plasminogen activator inhibitor-1 4G4G genotype is associated with myocardial infarction but not with stable coronary artery disease.
|
17721742 |
2008 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Synergistic effects of the polymorphisms in the PAI-1 and IL-6 genes with smoking in determining their associated risk with coronary artery disease.
|
18307986 |
2008 |
|
Coronary heart disease
|
0.100 |
Biomarker
|
disease |
LHGDN |
[Plasminogen activator inhibitor-1 (PAI-1): pathogenetic role in coronary disease].
|
17975760 |
2007 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Combined analyses of studies of the PAI-1 [-675] 4G variant yielded a per-allele relative risk for coronary disease of 1.06 (1.02-1.10), but there was an indication of publication bias in these studies.
|
16503463 |
2006 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Haplotype analyses confirmed the effects of the PAI-1 gene-smoking interaction on CHD risk.
|
16424345 |
2006 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The interleukin-6 (IL-6) gene promoter G-174C polymorphism has been associated with insulin resistance, hypertension, and coronary artery disease; however, its relationship with plasma PAI-1 level has not yet been studied.
|
15831362 |
2005 |
|
Coronary heart disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although the potential role of plasminogen activator inhibitor-1 (PAI-1) in the development of coronary artery disease is strongly supported by its biological characteristics, results of clinical studies remain controversial.
|
14629464 |
2003 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
[Association of plasminogen activator inhibitor-1 gene 4G/5G polymorphism and coronary heart disease in Chinese patients].
|
12362314 |
2002 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PAI-I 4G/5G polymorphism and sudden cardiac death in patients with coronary artery disease.
|
11457467 |
2001 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In linkage analysis there was no evidence for a linkage of the ACE or PAI-1 loci with CHD.
|
11427204 |
2001 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We found no associations between ACE I/D genotypes and plasma PAI-1 antigen concentrations in a subset of participants without major CHD risk factors (hypertension, hypercholesterolemia, overweight, smoking, diabetes) or in a small sample of African-Americans.
|
10997795 |
2000 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Plasminogen activator inhibitor-1 4G/5G promoter polymorphism and coagulation factor VII Arg353-->Gln polymorphism in Korean patients with coronary artery disease.
|
10803689 |
2000 |
|
Coronary heart disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The ApoE polymorphism may accelerate the development of coronary heart disease often seen in Caucasian patients with type 1 diabetes and diabetic nephropathy, a condition characterized by elevated plasma PAI-1 in men.
|
10809802 |
2000 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Single effects of apolipoprotein B, (a), and E polymorphisms and interaction between plasminogen activator inhibitor-1 and apolipoprotein(a) genotypes and the risk of coronary artery disease in Czech male caucasians.
|
10720441 |
2000 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction.
|
10577569 |
1999 |